Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
Gilead Sciences Announces Completion of Acquisition of CymaBay
09:18am, Friday, 22'nd Mar 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) f
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
07:11pm, Wednesday, 28'th Feb 2024
CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
04:45pm, Wednesday, 28'th Feb 2024
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
05:43pm, Wednesday, 21'st Feb 2024
- Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo - NEWARK, Calif.
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 20'th Feb 2024
NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CymaBay Ther
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
01:55pm, Monday, 12'th Feb 2024
Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billi
MILWAUKEE , Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY) for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead. Click
Why is CymaBay (CBAY) Stock Up 25% Today?
11:09am, Monday, 12'th Feb 2024
CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilea
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
09:35am, Monday, 12'th Feb 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) to Gilead Sciences, Inc. for $32.50 per share i
Gilead to buy CymaBay Therapeutics for $4.3 billion
09:33am, Monday, 12'th Feb 2024
CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
08:45am, Monday, 12'th Feb 2024
- FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif. , Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focuse
Drugmaker Gilead to acquire CymaBay for $4.3 bln
08:42am, Monday, 12'th Feb 2024
Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
Gilead strikes deal to acquire CymaBay for $4.3 billion
08:42am, Monday, 12'th Feb 2024
Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for
